The First Central Clinical College of Tianjin Medical University, Tianjin, China.
Department of Hematology, 66571Tianjin First Central Hospital, Tianjin, China.
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221118413. doi: 10.1177/15330338221118413.
Over the past few decades, immunotherapy has revolutionized the modern medical oncology field. Chimeric antigen receptor (CAR)-T cell therapy has a promising curative effect in the treatment of hematological malignancies. Anti-CD19 CAR-T cells are the most mature CAR-T cells recently studied and in recent years it has achieved a complete remission rate of approximately 90% in the treatment of B-cell acute lymphoblastic leukemia (B-ALL). Although CAR-T cell therapy has greatly alleviated the disease in patients with leukemia or lymphoma, some of them still relapse after treatment. Therefore, in this article, we discuss the factors that may contribute to disease relapse following CAR-T cell therapy and summarize potential strategies to overcome these obstacles, thus providing the possibility of improving standard treatment regimens.
在过去的几十年中，免疫疗法彻底改变了现代医学肿瘤学领域。嵌合抗原受体 (CAR)-T 细胞疗法在治疗血液系统恶性肿瘤方面具有有前景的疗效。抗 CD19 CAR-T 细胞是最近研究的最成熟的 CAR-T 细胞，近年来在治疗 B 细胞急性淋巴细胞白血病 (B-ALL) 方面已达到约 90%的完全缓解率。尽管 CAR-T 细胞疗法极大地缓解了白血病或淋巴瘤患者的疾病，但其中一些患者在治疗后仍会复发。因此，在本文中，我们讨论了可能导致 CAR-T 细胞治疗后疾病复发的因素，并总结了克服这些障碍的潜在策略，从而为改善标准治疗方案提供了可能性。
